We found that Gal-3 serum level was able to predict the functional outcome of AIS patients (AUC = 0.884, 95CI:0.827-0.941, P < 0.001) with sensitivity of 88.4% and specificity of 76.9% at the cut-off value of 53.5 as shown in Figure 3. This evidence concerns the gene LGALS3 and androgen insensitivity syndrome.